Global Preimplantation Genetic Testing Market Size Likely to Grow at a CAGR of 7.93% By 2034
Key highlights
- As per the industry experts at CMI, the global preimplantation genetic testing market will witness a stellar CAGR between 2025 and 2034.
- Aging Parents to Spell Growth: With more couples delaying parenthood, the likelihood of chromosomal abnormalities increases, which is boosting the use of PGT.
- Strengths: Preimplantation genetic testing helps in reducing miscarriages, raising rates of implantation with fewer cycles.
Market Size and Growth
As per the Preimplantation Genetic Testing Market size analysis conducted by the CMI team, the preimplantation genetic testing market is expected to record a CAGR of 7.93% from 2025 to 2034. In 2025, the market size was USD 936.12 Million. By 2034, the valuation is anticipated to reach USD 1863.7 Million.
Overview
As per the industry experts at CMI, the global preimplantation genetic testing market will witness a stellar CAGR between 2025 and 2034. This could be attributed to delayed childbearing, rising rates of infertility, rising awareness of genetic disorders, and technological advancements such as non-invasive preimplantation genetic testing (PGT), thereby resulting in better IVF outcomes (healthy babies, fewer miscarriages). The key factors encompass adoption of PGT by older couples (35-40+) and an increased demand for treatment for monogenic diseases.
Key Trends & Drivers
- Aging Parents to Spell Growth: With more couples delaying parenthood, the likelihood of chromosomal abnormalities increases, which is boosting the use of PGT. Also, growing awareness about conditions such as single-gene disorders (PGT-M) and down syndrome (PGT-A) does drive the demand. Advanced IVF infrastructure and novel screening methods such as non-invasive PGT are increasing adoption.
- Technological Advancements to Catalyze Growth: PGT does select healthy embryos, thereby reducing the risk of miscarriage and raising the success rate of single-embryo transfer. Expansion of tourist destinations such as China and India for treatments of fertility is another factor driving the preimplantation genetic testing market. Also, the PGT market is switching from a niche service to a mainstream IVF component, thereby emphasizing the delivery of healthier pregnancies via advanced genetic screening.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 936.12 Million |
| Projected Market Size in 2034 | USD 1863.7 Million |
| Market Size in 2024 | USD 867.34 Million |
| CAGR Growth Rate | 7.93% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Procedure, Product, Technology, Application, End-use and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
SWOT Analysis
- Strengths: Preimplantation genetic testing helps in reducing miscarriages, raising rates of implantation with fewer cycles. NGS does offer comprehensive and precise analysis. It also allows for selection of various healthy embryos for SET (single-embryo transfer). In the U.S. close to 16.6% of assisted reproductive technologies (ART) cycles involve preimplantation genetic testing.
- Weaknesses: Higher cost does make PGT inaccessible for numerous emerging economies. Also, the risk of false negatives/positives that could adversely affect selection of embryo can’t be ruled out. There are debates doing the rounds regarding embryo discarding and selection.
- Opportunities: The Asia-Pacific is the fastest growing region owing to rising awareness. Wider use for older maternal age and recurrent miscarriages is another opportunity. AI/ML can also be used for better interpretation of data. NGS facilitates high-resolution chromosomal analysis, especially in the women of advanced maternal age.
- Threats: The evolving guidelines are likely to adversely affect the cost and access to preimplantation genetic testing. Plus, many underdeveloped economies fail to provide insurance coverage, which compels the new entrants to give a second thought regarding the adoption of PGT.
List of the prominent players in the Preimplantation Genetic Testing Market:
- Quest Diagnostics Inc.
- Natera Inc.
- Cooper Surgical Inc.
- Genea Pty Limited
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific Inc.
- Bioarray S.L.
- Illumina Inc.
- Igenomix
- RGI
- Hoffmann-La Roche AG
- Others
The Preimplantation Genetic Testing Market is segmented as follows:
By Procedure
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
By Product
- Reagents and Consumables
- Instruments
- Software
By Technology
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescent In-Situ Hybridization (FISH)
By Application
- Chromosomal Abnormalities
- X-linked Diseases
- Embryo Testing
- Aneuploidy Screening
- HLA Typing
By End-use
- Fertility Centers
- Hospitals
- Diagnostic Centers
- Research Centers & Academic Labs
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Rushikesh Dorge
View profile and reportsAbout Custom Market Insights
Custom Market Insights is a market research and advisory company. It publishes syndicated reports across 18+ industries and delivers custom research, feasibility studies and market entry strategy for companies, investors and consultancies.
###